Chronic Lymphocytic Leukemia

Featured

News
Acalabrutinib demonstrated favorable PFS and OS compared with standard first-line treatments for CLL, according to a systematic review and network meta-analysis.
Quiz
True or False: First-line acalaburitnib plus obinutuzmumab prolongs progression-free survival compared to ibrutinib-…
Videos
Tara Graff, DO, explains how the introduction of acalabrutinib has impacted the treatment of CLL.
Videos
Alexey Danilov, MD, PhD, discusses acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
News
First-line acalaburitnib plus obinutuzmumab prolongs PFS compared to ibrutinib-obinutuzumab and venetoclax-obinutuzumab…